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ABSTRACT 
A pregnant woman who happens on a continuous exposure to various therapeutic agents during her gestation period may give birth to a 
neonate suffering from Neonatal Syndrome. The most common cause of NAS are opioids such as heroin, codeine and morphine and is 
commonly termed as opioid withdrawal syndrome but also other legally or illegally  sold substances over the counter can contr ibute to this 
syndrome. Infants also develop some kind of addition in the womb when exposed to some antidepressants such as barbiturates and 
benzodiazepine. There are two kinds of NAS that exist, prenatal NAS which is as a result of the termination of medication being used with a 
pregnant mother and postnatal NAS which occurs as a result of the termination of drugs directly to the infant.  The most frequently occurring 
syndrome consists of tremor, insomnia, perspiration, Common syndrome according to the frequency includes tremor, high-pitched sneezing 
sound, increased muscle tone, regurgitation and emesis, loose stools, s, excoriation, mottling, nasal congestion low-grade fever, and tachypnea. 
Opioid withdrawal symptoms can be a reflection of other symptoms of other conditions in a new-born, such as infections, hypoglycaemia, 
hypocalcaemia, hypothyroidism, and brain complications (eg., cerebral palsy). The need and time frame of treatment is reduced by 
breastfeeding. All NAS babies need to be followed up regularly. Not all infants will require treatment with pharmacotherapy, but all should 
receive non-pharmacologic interventions. 
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INTRODUCTION 
Neonatal abstinence syndrome (NAS) is described as a 
sequence of symptoms typically witnessed in the new-born 
of a mother who has taken opioids and other drugs for a long 
duration period in the antepartum period (Jansson et al., 
2012). Withdrawal symptoms tend to occur in new-borns 
who no longer receive opioids that had been systemically 
delivered via the placenta immediately after parturition. The 
implications of NAS usually appear with an onset of 
symptoms on the fifth day of life depending on the type of 
medication received by the mother and lasting up to six 
months of age (Shearer et al., 2018). 
ETIOLOGY 
There are two major kinds of NAS. The prenatal NAS is the 
most widely known and occurs commonly in antepartum use 
of substances. Withdrawal symptoms appear in the neonate 
once the placental access to the drug is no longer at its 
disposal. Postnatal NAS develops in sudden termination of 
analgesics, such as Fentanyl or morphine, occurs usually 
after one being exposed to for a very long time after surgery 
for management of pain to cause sedation (Nancy et al., 
2014). 
PATHOPHYSIOLOGY OF NAS 
The pathophysiological mechanism that results in opioid 
withdrawal syndrome in neonates is an idiopathic case. 
Numerous factors can affect the build-up of opioids in the 
fetus. Opiate drugs have low molecular weights, are 
hydrophilic in nature, and are lipophilic substances; hence, 
they easily pass across the placenta membrane to the fetus. 
There is a direct relationship between opioid transportation 
across the placenta and gestation. Transportation of opioids 
increases with an increase in gestation (Nanovskaya et al., 
2008). Opioid deficiency also alters the functioning of the 
autonomic and peripheral nervous systems, as well as the 
gastrointestinal system. Opioid deficits cause increased 
release of a variety of neurotransmitters, such as 
acetylcholine, during the phase of withdrawal (Passo et al., 
2011). Neonates whose mothers used an SSRI or SNRI may 
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result in profuse production of serotonin and noradrenaline 
as withdrawal symptoms.  Neonatal withdrawal from TCA is 
a cholinergic rebound phenomenon. There is a high 
possibility in increasing production of amino acid as a result 
of withdrawing benzodiazepine (Sanj et al., 2005). 
MANAGEMENT 
The core objective as regards to the management of NAS is to 
encourage normal growth development. Primary concerns 
regarding the management of the NAS is to promote normal 
growth development and to avert or reduce negative effects 
such as convulsions and discomfort in the new-born and 
impaired maternal bonding (Kraft et al., 2016).  
NONPHARMACOLOGIC THERAPY 
All children at risk of NAS need to be taken care through a 
non-chemotherapeutic approach aimed at providing a 
peaceful and calming atmosphere while avoiding excessive 
stimulation of environment. Frequent high-calorie foods 
reduce hunger and promote growth (Jansson et al., 2009). 
Non-nutritious absorption helps reduce stress in the child 
and has irregular and irregular movements (Velez et al., 
2008). 
PHARMACOLOGIC THERAPY 
Pharmacotherapy is an indispensable part of management 
when nonpharmacological care is inadequate to relieve the 
complications associated with neonatal abstinence 
syndrome. About 20% to 40% of children with the syndrome 
do respond to non-pharmacological remedies and don’t 
require medication (Kocherlakota, P., 2014). The core 
objective weight loss of pharmacologic therapy is to relieve 
moderate-to-severe signs such as seizures, fever, and weight 
loss (Hudak et al., 2012). AAP guidelines based on current 
evidence and practice in the United States demonstrates oral 
morphine and methadone as first-line therapies. (Jansson et 
al.2009). Clonidine and phenobarbital concentrations can be 
closely checked and both play a vital role in reducing the 
duration of therapy as well as cut back the use of higher 
doses of morphine or methadone (Kuschel, C., 2007; Agthe et 
al.,2009). Delays in pharmacologic treatment intervention 
are linked to higher morbidity and longer hospitalization 
periods. (Finnegan et al., 1992) 
LONG TERM EFFECT 
Evaluation of the long-term effect of NAS has been a major 
problem due to the scarcity of research opportunities. 
Symptoms often begin within one to three days after birth 
but may take up to a week to appear. Newborns with NAS 
may exhibit abnormal behaviors up to 6 to 9 months of age 
(Behnke et al., 2013). Adverse neurodevelopmental 
syndromes have been observed in infants and children 
exposed to opioids in utero. There is relatively scanty 
information on long-term neurodevelopmental implications. 
This is especially due to scanty studies that are not in a 
position to distinguish between the effects of in 
utero exposures and postnatal treatments with 
environmental variables influences. In general, opioid-
exposed children are at high risk to have attention deficit 
disorders, disruptive behavior, and the need for 
comprehensive psychiatric referrals (Ornoy et al., 2010)  
BREAST FEEDING 
American Academy of Paediatrics in 2001 rejected any the 
restrictions on lactating mothers on any dosage of 
methadone (American Academy et al.2001). Breastfeeding 
may reduce the incidence of NAS (Welle-Strand et al., 2013). 
OPIOIDS 
Morphine and Methadone: 
The two major opioids that have found relevance in practice 
are oral morphine and methadone. Morphine is the primary 
opioid used in most of the centers, with methadone being 
used in 10–20% of hospitals (Patrick et al., 2014). Normally 
the doses start from 0.2 mg/kg/day. Some treatment 
regimens require a loading dose of 0.1 mg/kg (Lainwala et 
al., 2005).  
Buprenorphine: 
Buprenorphine a partial opioid agonist is a new addition in 
NAS treatment. A long half-life (approximately 20 hours, 
based on limited data from premature infants (Barrett et al 
1993). 
Clonidine: 
Clonidine acts centrally and decreases global sympathetic 
flow and is administered in adult experiencing withdrawal 
syndromes. Clonidine is less effective in adults in comparison 
with opioids in the management of withdrawal symptoms 
(Gowing et al., 2009). 
Phenobarbital: 
Phenobarbital is a barbiturate anticonvulsant. It is mostly 
administered as adjuvant therapy once the opiate dose is 
attained, it can be used as a key adjuvant with opioids or as a 
single primary therapy (Coyle et al., 2002). The 
phenobarbital half-life in neonates is 115 hours at 1 week 
and reduces to 67 hours after 4 weeks (Pitlick et al., 1978).  
Treatment: 
 The best therapeutic remedy should seek to strike a balance 
between safety and effective care and also factor in the 
pharmacoeconomics aspect in the entire plan. .Apart from 
the treatment of NAS, many of these infants has pressing 
medical and social issues that require to be admitted in 
hospital. Physicians may consider weaning by volume to 
simplify dosage for parents and eradicate error. (Kuschel, C., 
2007). 
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CNS = central nervous system; DTO. 
a Hudak & Tan (2012), Langenfeld et al. (2005), Ebner et al. 
(2007), Jackson et al. (2004). 
b Bio et al. (2011), Jones et al. (2010). 
c AAP (2012), Agthe et al. (2009), Leikin et al. (2009). 
d Jones et al. (2010), Kraft et al. (2011). 
e Langenfeld et al. (2005). 
f Bio et al. (2011), Coyle, Ferguson, LaGasse, Liu, and Lester 
(2005), Isemann et al. (2011), Langenfeld et al. (2005). 
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CONCLUSION 
 The prevalence of NAS is increasing for infants exposed to 
opioids or recreational drugs in antepartum period. Since 
there is no specific remedy for infants, most systems rely on 
pharmacotherapy. Non-pharmacological and alternative 
therapies, although available have not gotten much attention 
in the literature. The huge consensus is to develop non-drug 
plan for entire predisposed children, to a need for 
pharmacological intervention, and evaluate their 
effectiveness frequently. Phenobarbital has been shown to be 
effective in the treatment of seizures associated with opioid 
withdrawal. It has been demonstrated that clonidine is 
effective and safe and is used as a second line drug treatment 
for NAS, which are resistant to opioid therapy. The 
concentration of methadone or buprenorphine present in 
breast milk is minute to treat NAS, so abrupt cessation of 
breast milk is not linked with exacerbation of NAS. 
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